A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis (Q35064496)

6 August 2017

1 reference

title

A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis (English)

1 reference

6 August 2017

0 references

Jingwu Zhang

1

1 reference

6 August 2017

George Hutton

series ordinal

2

1 reference

6 August 2017

Ying Zang

series ordinal

3

1 reference

6 August 2017

language of work or name

1 reference

1 December 2002

1 reference

6 August 2017

published in

Clinical Therapeutics

1 reference

6 August 2017

volume

24

1 reference

6 August 2017

issue

12

1 reference

6 August 2017

page(s)

1998-2021

1 reference

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Mechanisms of action of interferon-beta in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

The interferons: biological effects, mechanisms of action, and use in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

The immune system. First of two parts

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

The immune system. Second of two parts

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

The control of T cell responses by dendritic cell subsets

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

How cells respond to interferons

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Elevated CD40 ligand expressing blood T-cell levels in multiple sclerosis are reversed by interferon-beta treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Interferon beta induces T-helper 2 immune deviation in MS

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Recombinant Interferon-β blocks proliferation but enhances interleukin-10 secretion by activated human T-cells

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Dendritic cells derived from patients with multiple sclerosis show high CD1a and low CD86 expression

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Altered phenotype and function of blood dendritic cells in multiple sclerosis are modulated by IFN-beta and IL-10.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Interferon-beta induces the development of type 2 dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Immunomodulatory effects of interferon beta-1a in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Interferon beta in multiple sclerosis: is IL-12 suppression the key?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

IFN-beta differentially regulates CD40-induced cytokine secretion by human dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Circulating natural killer cells but not cytotoxic T lymphocytes are reduced in patients with active relapsing multiple sclerosis and little clinical disability as compared to controls

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Natural killer cells in antiviral defense: function and regulation by innate cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Natural killer cell activity in patients with multiple sclerosis given alpha interferon.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

A role for natural killer cells in the immunopathogenesis of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Effect of IFNbeta and anti-IFNbeta antibodies on NK cells in multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Interferon beta1a treatment modulates TH1 expression in gammadelta + T cells from relapsing-remitting multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Low serum interleukin-10 levels in multiple sclerosis: further evidence for decreased systemic immunosuppression?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Relationship between serum levels of IL-10, MRI activity and interferon beta-1a therapy in patients with relapsing remitting MS

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

The pattern of production of cytokine mRNAs is markedly altered at the onset of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Defective regulation of IFNgamma and IL-12 by endogenous IL-10 in progressive MS

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Increased in vitro induced CD4+ and CD8+ T cell IFN-gamma and CD4+ T cell IL-10 production in stable relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Following direct CD40 activation, human primary microglial cells produce IL-12 p40 but not bioactive IL-12 p70.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Increased release of interleukin-12p40 in MS: association with intracerebral inflammation.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

IL-12/IL-12R system in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Interferon-beta in multiple sclerosis: altering the balance of interleukin-12 and interleukin-10?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Modulation of the IL-10/IL-12 cytokine circuit by interferon-beta inhibits the development of epitope spreading and disease progression in murine autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

1 reference

7 January 2021

Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

IFN-beta-1b inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10-dependent mechanism: relevance to IFN-beta-1b therapeutic effects in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Immunoregulation and blocking antibodies induced by interferon beta treatment in MS

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Interferon-β treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-γ and interleukin-4

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Late complications of immune deviation therapy in a nonhuman primate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Aberrant T cell migration toward RANTES and MIP-1 alpha in patients with multiple sclerosis. Overexpression of chemokine receptor CCR5.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1alpha by interferon-beta

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Metalloproteinases and their tissue inhibitors in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Changes of serum sICAM-1 and MMP-9 induced by rIFN -1b treatment in relapsing-remitting MS

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

The distinction blurs between an autoimmune versus microbial hypothesis in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Association between clinical disease activity and Epstein-Barr virus reactivation in MS.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Anti-viral properties of interferon beta treatment in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Copolymer-1-induced inhibition of antigen-specific T cell activation: interference with antigen presentation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Synthetic peptides that inhibit binding of the myelin basic protein 85-99 epitope to multiple sclerosis-associated HLA-DR2 molecules and MBP-specific T-cell responses

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Mechanisms of action of glatiramer acetate in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Mechanisms of immunomodulation by glatiramer acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Glatiramer acetate (GA) induces IL-13/IL-5 secretion in naive T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Combination therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFN-alpha) does not improve experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

An improved in vitro assay to quantitate chemotaxis of rat peripheral blood large granular lymphocytes (LGL)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Quantitation of neutralization of interferon by antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-beta1a

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Multiple sclerosis: deficient in vitro responses of blood mononuclear cells to IFN-beta

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

Lymphocyte migration and multiple sclerosis: relation with disease course and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980094-7

7 January 2021

10.1016/S0149-2918(02)80094-7

Identifiers

DOI

1 reference

6 August 2017

1 reference